Search results for "FDA update"
New GLP-1 agonist approved
A new glucagon-like peptide-1 (GLP-1) receptor agonist, dulaglutide (Trulicity), was approved to treat type 2 diabetes, along with diet and exercise, the FDA recently announced.
https://diabetes.acponline.org/archives/2014/10/10/8.htm
10 Oct 2014
New weight loss device approved
A new balloon device (the ReShape Dual Balloon) was recently approved by the FDA to treat obesity without invasive surgery.
https://diabetes.acponline.org/archives/2015/08/14/6.htm
14 Aug 2015
Rosiglitazone REMS ends, new insulin approved
The FDA has determined that the Risk Evaluation and Mitigation Strategy is no longer necessary to ensure that the benefits of rosiglitazone-containing drugs outweigh their risks.
https://diabetes.acponline.org/archives/2016/01/08/6.htm
8 Jan 2016
Abbot FreeStyle Insulinx meters recalled
The Abbott FreeStyle Insulinx blood glucose meters were recently recalled because at extremely high blood glucose levels of 1,024 mg/dL and above, the meters will display and store in memory an incorrect test result that is 1,024 mg/dL below the measured result.
https://diabetes.acponline.org/archives/2013/07/12/9.htm
12 Jul 2013
Canagliflozin will receive new boxed warning about amputation risks
Canagliflozin (Invokana, Invokamet) increases patients' risk of leg and foot amputations, according to new data from two clinical trials, the FDA recently announced.
https://diabetes.acponline.org/archives/2017/06/09/7.htm
9 Jun 2017
Hemoglobin A1c test approved for diagnosis
The FDA recently approved the first hemoglobin A1c (HbA1c) test specifically labeled for diagnosing diabetes.
https://diabetes.acponline.org/archives/2013/08/09/8.htm
9 Aug 2013
Empagliflozin approved to treat type 2 diabetes
Empagliflozin (Jardiance), a sodium glucose co-transporter 2 inhibitor, was recently approved to treat type 2 diabetes in addition to diet and exercise, the FDA announced last week.
https://diabetes.acponline.org/archives/2014/08/08/5.htm
8 Aug 2014
Warning on DPP-4 inhibitors and insulin recall
Dipeptidyl peptidase-4 (DPP-4) inhibitors may cause joint pain that can be severe and disabling, and some insulin pods may fail, the FDA recently warned.
https://diabetes.acponline.org/archives/2015/09/11/6.htm
11 Sep 2015